Angiogenesis, p53, and bcl-2 expression as prognostic indicators in endometrial cancer: Comparison with traditional clinicopathologic variables

International Journal of Gynecological Pathology

Volumn 22, Issue 3, 2003, Pages 254-260

  Erdem, Ozlem ^a,b   Erdem, Mehmet ^a   Dursun, Ayse ^a   Akyol, Gulen ^a   Erdem, Ahmet ^a  

^a GAZI UNIVERSITY   (Turkey)

^b NONE   (Turkey)

Author keywords

bcl 2; Endometrial cancer; Immunohistochemistry; Microvessel density; p53; Survival

Indexed keywords

CD34 ANTIGEN; PROTEIN BCL 2; PROTEIN P53;

ADULT; AGE; AGED; ANGIOGENESIS; ARTICLE; CANCER GRADING; CANCER INVASION; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CELL NUCLEUS; CLINICAL FEATURE; CONTROLLED STUDY; CYTOPLASM; ENDOMETRIUM CANCER; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYSTERECTOMY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MICROVASCULATURE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SALPINGOOOPHORECTOMY; TUMOR SUPPRESSOR GENE;

ADENOCARCINOMA; ADULT; AGED; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MICROCIRCULATION; MIDDLE AGED; MYOMETRIUM; NEOPLASM INVASIVENESS; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; REGRESSION ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0037531405     PISSN: 02771691     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.PGP.0000070850.25718.A5     Document Type: Article

References (47)

1. Greenlee RT, Murray T, Bolden S, et al. Cancer statistics, 2000. Cancer J Clin 2000;50:7-33.
2. Homsley H, Zaino R. Endometrial cancer: prognostic factors. Semin Oncol 1994;21:71-8.
3. Nogales FF. Prognostic factors in endometrial neoplasia: old and new. Curr Opin Obstet Gynecol 1996;8:74-8.
4. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1989;82:4-6.
5. Weidner N. Intratumor microvessel density as a prognostic factor in cancer. Am J Pathol 1995;147:9-19.
6. Hollstein M, Sidransky D, Vogelstein B, et al. p53 mutations in human cancers. Science 1991;253:49-53.
7. Vaux DL. Toward an understanding of the molecular mechanisms of physiological cell death. Proc Natl Acad Sci USA 1993;90:786-9.
8. Levine AJ. The role of p53 as a tumor suppressor gene in human cancers. Adv Oncol 1993;8:3-9.
9. Kastan MB, Onyekwere O, Sidransky B, et al. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 1991;51:6304-11.
10. Dameron KM, Volpert OV, Tainsky MA, et al. Control of angiogenesis in fibroblasts by p53 regulation of trombospondin-1. Science 1994;265:1582-4.
11. Geisler JP, Geisler HE, Wiemann MC, et al. p53 expression as a prognostic indicator of 5-year survival in endometrial cancer. Gynecol Oncol 1999;74:468-71.
12. Naito M, Satake M, Sakai E, et al. Detection of p53 gene mutation in human ovarian and endometrial cancers by polymerase chain reaction-single strand conformation polymorphism analysis. Jpn J Cancer Res 1992;83:1030-6.
13. Berchuck A, Kohler MF, Marks JR, et al. The p53 tumor suppressor gene frequently is altered in gynecologic cancers. Am J Obstet Gynecol 1994;170:246-52.
14. Fox SB. Tumor angiogenesis and prognosis. Histopathology 1997;30:294-301.
15. Weidner N, Semple JP, Welch WR, et al. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 1991;324:1-8.
16. Kaku T, Kamura T, Kinukawa N, et al. Angiogenesis in endometrial carcinoma. Cancer 1997;80:741-7.
17. Bargou RC, Daniel PT, Mapara MY, et al. Expression of bcl-2 gene family in normal and malignant breast tissue: low bax-a expression in tumor cells correlates with resistance toward apoptosis. Int J Cancer 1996;60:854-9.
18. Geisler JP, Geisler HE, Wiemann MC, et al. Lack of bcl-2 persistence: an independent prognostic indicator of poor prognosis in endometrial carcinoma. Gynecol Oncol 1998;71:305-7.
19. Mikuta JJ. International Federation of Gynecology and Obstetrics staging of endometrial cancer. Cancer 1993;71:1460-3.
20. Taskin M, Lallas TA, Barber HRK, et al. bcl-2 and p53 in endometrial adenocarcinoma. Mod Pathol 1997;10:728-34.
21. Salvesen HB, Iversen OE, Akslen LA. Prognostic significance of angiogenesis and Ki-67, p53, and p21 expression: a population-based endometrial carcinoma study. J Clin Oncol 1999;17:1382-90.
22. Hoffman K, Nekhlyudar L, Deligclisch L. Endometrial carcinoma in elderly women. Gynecol Oncol 1995;58:198-201.
23. Behbakht K, Yordan EL, Casey C, et al. Prognostic indicators of survival in advanced endometrial cancer. Gynecol Oncol 1994;55:363-7.
24. Chen PL, Chen YM, Bookstein R, et al. Genetic mechanisms of tumor suppression by the human p53 gene. Science 1990;250:1576-80.
25. Ioffe OB, Papadinitriou JC, Drachenberg CB. Correlation of proliferation indices, apoptosis, and related oncogene expression (bcl-2 and c-erb-2) and p53 in proliferative, hyperplastic, and malignant endometrium. Hum Pathol 1998;29:1150-9.
26. Zheng W, Cao P, Zheng M, et al. p53 overexpression and bcl-2 persistence in endometrial carcinoma: comparison of papillary serous and endometrioid subtypes. Gynecol Oncol 1996;61:167-74.
27. Geisler JP, Wiemann MC, Zhou Z, et al. p53 as a prognostic indicator in endometrial cancer. Gynecol Oncol 1996;61:245-8.
28. Backe J, Gassel AM, Hauber K, et al. p53 protein in endometrial cancer is related to proliferative activity and prognosis but not to expression of p21 protein. Int J Gynecol Pathol 1997;16:361-8.
29. Nielsen AL, Nyholm HC. p53 and c-erb-2 protein expression in endometrial adenocarcinoma of endometrioid type. Am J Clin Pathol 1994;102:76-9.
30. Pisani AL, Barbuto DA, Chen D, et al. HER-2/neu, p53, and DNA analysis as prognosticators for survival in endometrial carcinoma. Obstet Gynecol 1995;85:729-34.
31. Soong R, Snowles S, Williams KE, et al. Overexpression of p53 protein is an independent prognostic indicator in human endometrial carcinoma. Br J Cancer 1996;74:562-7.
32. Gassel AM, Backe J, Krebs S, et al. Endometrial carcinoma: immunohistochemically detected proliferation index is a prognosticator of long term outcome. J Clin Pathol 1998;51:25-9.
33. Reinartz JJ, George E, Lindgren BR, et al. Expression of p53, transforming growth factor alpha, epidermal growth factor receptor, and c-erb-2 in endometrial carcinoma and correlation with survival and known predictors of survival. Hum Pathol 1994;25:1075-8.
34. Ito K, Sasano H, Matsunaga G, et al. Correlations between p21 expression and clinicopathological findings, p53 gene and protein alterations, and survival in patients with endometrial carcinoma. J Pathol 1997;183:318-24.
35. Van Slooten HJ, van de Vivjer, van de Velde CJ, et al. Loss of bcl-2 in invasive breast cancer is associated with high rates of cell death, but also with increased proliferative activity. Br J Cancer 1998;77:789-96.
36. Otsuki Y, Misaki O, Sugimoto O, et al. Cyclic bcl-2 gene expression in human uterine endometrium during menstrual cycle. Lancet 1994;344:28-9.
37. Gompel A, Sabourin JC, Martin A, et al. Bcl-2 expression in normal endometrium during the menstrual cycle. Am J Pathol 1994;144:1195-202.
38. Chan WK, Mole MM, Levison DA, et al. Nuclear and cytoplasmic bcl-2 expression in endometrial hyperplasia and adenocarsinoma. J Pathol 1995;177:241-6.
39. Henderson GS, Brown KA, Perkins SL, et al. Bcl-2 is down-regulated in atypical endometrial hyperplasia and adenocarcinoma. Mod Pathol 1996;9:430-8.
40. Yamauchi N, Sakamato A, Uozaki H, et al. Immunohistochemical analysis of endometrial adenocarcinoma for bcl-2 and p53 in relation to expression of sex steroid receptor and proliferative activity. Int J Gynecol Pathol 1996;15:202-8.
41. Sakuragi N, Ohkouchi T, Hareyama H, et al. Bcl-2 expression and prognosis of patients with endometrial carcinoma. Int J Cancer 1998;79:153-8.
42. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenetic switch during tumorigenesis. Cell 1996;86:353-64.
43. Weidner N, Folkman J, Pozza F, et al. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 1992;84:1875-87.
44. Holmgren L, O'Reilly MS, Folkman J. Dormancy of micrometastasis: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nature Med 1995;1:49-53.
45. Abulafia O, Triest WE, Sherer DM, et al. Angiogenesis in endometrial hyperplasia and stage I endometrial carcinoma. Obstet Gynecol 1995;86:479-85.
46. Salvesen HB, Iversen OE, Akslen LA. Independent prognostic importance of microvessel density in endometrial carcinoma. Br J Cancer 1998;77:1140-4.
47. Kirschner CV, Alanis-Amezcua JM, Martin VG, et al. Angiogenesis factor in endometrial carcinoma: a new prognostic indicator? Am J Obstet Gynecol 1996;174:1879-84.